EU panel supports broader approval of Pfizer's Prevenar 13

09/25/2011 | Reuters

People age 50 and older should be allowed to receive Prevenar 13, a pneumococcal vaccine by Pfizer, said the European Medicines Agency's Committee for Medicinal Products for Human Use. The vaccine is indicated for younger children in the EU and the U.S., where it is marketed as Prevnar 13. The FDA previously asked for more time to evaluate the wider use.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC